statistiche ricercatore

Continente	#
AS - Asia	460
NA - Nord America	325
EU - Europa	245
SA - Sud America	60
AF - Africa	16
OC - Oceania	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.109

Nazione	#
US - Stati Uniti d'America	307
SG - Singapore	191
RU - Federazione Russa	142
CN - Cina	92
VN - Vietnam	83
BR - Brasile	44
IT - Italia	28
HK - Hong Kong	25
DE - Germania	23
BD - Bangladesh	16
KR - Corea	16
AR - Argentina	12
FR - Francia	11
CA - Canada	9
IN - India	8
NL - Olanda	8
GB - Regno Unito	7
JP - Giappone	6
ZA - Sudafrica	6
FI - Finlandia	5
CI - Costa d'Avorio	4
TH - Thailandia	4
TR - Turchia	4
AT - Austria	3
EC - Ecuador	3
IE - Irlanda	3
IQ - Iraq	3
MX - Messico	3
PK - Pakistan	3
SE - Svezia	3
AU - Australia	2
CR - Costa Rica	2
ES - Italia	2
KE - Kenya	2
PH - Filippine	2
PL - Polonia	2
UA - Ucraina	2
AL - Albania	1
BE - Belgio	1
BH - Bahrain	1
BS - Bahamas	1
CO - Colombia	1
CW - ???statistics.table.value.countryCode.CW???	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
DZ - Algeria	1
EG - Egitto	1
ET - Etiopia	1
HR - Croazia	1
JO - Giordania	1
KZ - Kazakistan	1
MY - Malesia	1
MZ - Mozambico	1
NI - Nicaragua	1
RO - Romania	1
SI - Slovenia	1
SV - El Salvador	1
TJ - Tagikistan	1
TW - Taiwan	1
UZ - Uzbekistan	1
Totale	1.109

Nome	#
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort	176
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort	158
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination	149
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort	130
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort	129
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)	128
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort	126
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort	124
Totale	1.120

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	6	0	0	0	0	0	0	0	0	0	1	3	2
2022/2023	20	1	2	0	1	4	0	1	2	5	4	0	0
2023/2024	32	0	7	6	3	1	4	0	4	0	0	5	2
2024/2025	324	14	3	0	12	19	23	29	26	12	33	127	26
2025/2026	735	77	70	80	70	102	33	106	31	77	48	41	0
Totale													1.120